Derivados de carboxamidina e seu uso no tratamento de doenças vasculares
"DERIVADOS DE CARBOXAMIDINA E SEU USO NO TRATAMENTO DE DOENçAS VASCULARES". A presente invenção refere-se a derivados de carboxamidina para composições farmacêuticas que os contenham e ao uso dos mesmos na preparação de composições farmacêuticas para o tratamento de doenças vasculares. Car...
Saved in:
Main Authors | , , , , |
---|---|
Format | Patent |
Language | Portuguese |
Published |
28.12.2004
|
Edition | 7 |
Online Access | Get full text |
Cover
Loading…
Abstract | "DERIVADOS DE CARBOXAMIDINA E SEU USO NO TRATAMENTO DE DOENçAS VASCULARES". A presente invenção refere-se a derivados de carboxamidina para composições farmacêuticas que os contenham e ao uso dos mesmos na preparação de composições farmacêuticas para o tratamento de doenças vasculares.
Carboxamidine derivatives (I)-(III) are used for treating or preventing vascular diseases. Carboxamidine derivatives of formula (I)-(III) or their salts are used for treating or preventing vascular diseases. R 1>, R 2>1-6C alkyl (optionally substituted by phenyl), or H, or NR 1>R 2>T; T : 5-7 membered saturated heterocyclyl optionally containing further N or O heteroatoms (optionally substituted by 1 or 2 OH, oxo or benzyl); A : phenyl (optionally substituted by 1 or 2 1-4C alkyl, 1-4C haloalkyl, NO 2or CN), or 5- or 6-membered heteroaryl containing at least one N, O or S and optionally having an N-oxide structure on the N heteroatom; n : 0-2; z : 0 or 1; X : halo or NR 4>R 5>; R 3>-R 5>H or 1-6C alkyl; Y : H, OH, halo or 1-22C acyloxy, and X 1>O, provided that: (1) when R 4>and R 5>are simultaneously H, then Y is not OH; (2) when Y is not halo, then NR 1>R 2>is T, A is N-containing heteroaryl optionally having a N-oxide structure on the N heteroatom and z is 1; (3) when X is halo and Y is hydroxy or acyloxy, then NR 1>R 1>is T; (4) when R 1>and R 2>are 1-6C alkyl (optionally substituted by phenyl), H, and NR 1>R 2>is 5-7 membered saturated heterocyclyl containing N or O, then A is heteroaryl containing O, S or N-containing heteroaryl having a N-oxide structure on the N heteroatom; and (5) when A is phenyl (optionally substituted by 1 or 2 1-4C alkyl, 1-4C haloalkyl, NO 2or halo), or 5- or 6-membered N-containing heteroaryl, then NR 1>R 2>is T. N.B: The formulae (I)-(III) are not shown in the specification. Independent claims are included for the following: (1) new compounds (I), with the further proviso that when Y is H and/or X is NR 4>R 5>, then NR 1>R 2>is T or A is N-containing heteroaryl optionally having an N-oxide structure on the N heteroatom; (2) new compounds (II), with the further proviso that when Y is not halo, then NR 1>R 2>is T and A is N-containing heteroaryl optionally having a N-oxide structure on the N heteroatom, and (3) new compounds (III). ACTIVITY : Vasotropic; Cardiovascular-Gen. In a wounding migration assay in an endothelial cell culture using wounded monolayers of human umbilical vein endothelial cells (HUVEC), results showed that N-[2-chloro-3-(1-piperidinyl)propoxy]-3-nitro-benzimidoyl-chloride hydrochloride gave number of cells/mm 2>at 24 hours of 60, compared to 30 for 5,6-dihydro-5-(1-piperidinyl)-methyl-3-(3-pyridyl)-4H-1,2,4-oxadiazine used as a control. MECHANISM OF ACTION : None given. |
---|---|
AbstractList | "DERIVADOS DE CARBOXAMIDINA E SEU USO NO TRATAMENTO DE DOENçAS VASCULARES". A presente invenção refere-se a derivados de carboxamidina para composições farmacêuticas que os contenham e ao uso dos mesmos na preparação de composições farmacêuticas para o tratamento de doenças vasculares.
Carboxamidine derivatives (I)-(III) are used for treating or preventing vascular diseases. Carboxamidine derivatives of formula (I)-(III) or their salts are used for treating or preventing vascular diseases. R 1>, R 2>1-6C alkyl (optionally substituted by phenyl), or H, or NR 1>R 2>T; T : 5-7 membered saturated heterocyclyl optionally containing further N or O heteroatoms (optionally substituted by 1 or 2 OH, oxo or benzyl); A : phenyl (optionally substituted by 1 or 2 1-4C alkyl, 1-4C haloalkyl, NO 2or CN), or 5- or 6-membered heteroaryl containing at least one N, O or S and optionally having an N-oxide structure on the N heteroatom; n : 0-2; z : 0 or 1; X : halo or NR 4>R 5>; R 3>-R 5>H or 1-6C alkyl; Y : H, OH, halo or 1-22C acyloxy, and X 1>O, provided that: (1) when R 4>and R 5>are simultaneously H, then Y is not OH; (2) when Y is not halo, then NR 1>R 2>is T, A is N-containing heteroaryl optionally having a N-oxide structure on the N heteroatom and z is 1; (3) when X is halo and Y is hydroxy or acyloxy, then NR 1>R 1>is T; (4) when R 1>and R 2>are 1-6C alkyl (optionally substituted by phenyl), H, and NR 1>R 2>is 5-7 membered saturated heterocyclyl containing N or O, then A is heteroaryl containing O, S or N-containing heteroaryl having a N-oxide structure on the N heteroatom; and (5) when A is phenyl (optionally substituted by 1 or 2 1-4C alkyl, 1-4C haloalkyl, NO 2or halo), or 5- or 6-membered N-containing heteroaryl, then NR 1>R 2>is T. N.B: The formulae (I)-(III) are not shown in the specification. Independent claims are included for the following: (1) new compounds (I), with the further proviso that when Y is H and/or X is NR 4>R 5>, then NR 1>R 2>is T or A is N-containing heteroaryl optionally having an N-oxide structure on the N heteroatom; (2) new compounds (II), with the further proviso that when Y is not halo, then NR 1>R 2>is T and A is N-containing heteroaryl optionally having a N-oxide structure on the N heteroatom, and (3) new compounds (III). ACTIVITY : Vasotropic; Cardiovascular-Gen. In a wounding migration assay in an endothelial cell culture using wounded monolayers of human umbilical vein endothelial cells (HUVEC), results showed that N-[2-chloro-3-(1-piperidinyl)propoxy]-3-nitro-benzimidoyl-chloride hydrochloride gave number of cells/mm 2>at 24 hours of 60, compared to 30 for 5,6-dihydro-5-(1-piperidinyl)-methyl-3-(3-pyridyl)-4H-1,2,4-oxadiazine used as a control. MECHANISM OF ACTION : None given. |
Author | EDE MARVANYOS MAGDOLNA BATHONE TOROK ZITA JEGESNE CSAKAI LASZLO DENES LASZLO UROGDI |
Author_xml | – fullname: LASZLO DENES – fullname: ZITA JEGESNE CSAKAI – fullname: MAGDOLNA BATHONE TOROK – fullname: LASZLO UROGDI – fullname: EDE MARVANYOS |
BookMark | eNqFyjsKwkAQBuAttPB1BucCQiBgbH2irdiHMfsLC8lM2NkN3siDeDER7K2-5pu6kahg4i4HxDCwVyMPajje9cld8EGYQIZM2ZREKUVO3EGSfqNXyPvFRgNbk1uOsLkbP7g1LH7O3PJ0vO3PK_Raw3puIEj17lqUxbqqNtvy__gAXYc2NQ |
ContentType | Patent |
DBID | EVB |
DatabaseName | esp@cenet |
DatabaseTitleList | |
Database_xml | – sequence: 1 dbid: EVB name: esp@cenet url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP sourceTypes: Open Access Repository |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry Sciences |
Edition | 7 |
ExternalDocumentID | BR0306778A |
GroupedDBID | EVB |
ID | FETCH-epo_espacenet_BR0306778A3 |
IEDL.DBID | EVB |
IngestDate | Fri Jul 19 13:05:53 EDT 2024 |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | false |
Language | Portuguese |
LinkModel | DirectLink |
MergedId | FETCHMERGED-epo_espacenet_BR0306778A3 |
Notes | Application Number: BR20030306778 |
OpenAccessLink | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20041228&DB=EPODOC&CC=BR&NR=0306778A |
ParticipantIDs | epo_espacenet_BR0306778A |
PublicationCentury | 2000 |
PublicationDate | 20041228 |
PublicationDateYYYYMMDD | 2004-12-28 |
PublicationDate_xml | – month: 12 year: 2004 text: 20041228 day: 28 |
PublicationDecade | 2000 |
PublicationYear | 2004 |
RelatedCompanies | BIOREX KUTATO ES FEJLESZTO RT |
RelatedCompanies_xml | – name: BIOREX KUTATO ES FEJLESZTO RT |
Score | 2.6096041 |
Snippet | "DERIVADOS DE CARBOXAMIDINA E SEU USO NO TRATAMENTO DE DOENçAS VASCULARES". A presente invenção refere-se a derivados de carboxamidina para composições... |
SourceID | epo |
SourceType | Open Access Repository |
Title | Derivados de carboxamidina e seu uso no tratamento de doenças vasculares |
URI | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20041228&DB=EPODOC&locale=&CC=BR&NR=0306778A |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdR3LTsMwzBoDATcYoPHOAfVWQd_doUK0XTWQ9lA10G5T0mRiB5pp6YA_4kP4MdxqBS67RUlkOVb8jO0A3AjHyhjaGXonc23d5uiwMmZ0dNOZGYJarstpWeDcH7i9Z_tp4kwa8FrXwlR9Qj-q5ojIURnye1HJ68VfECuucivVLZvjlLxPxkGs1d6xbZimr8Vh0B0N42GkRVEQptogDSrT2PMftmAbjWiv5IXuS1jWpCz-K5TkAHZGCCsvDqGxKFqwF9X_rrVgt79-7sbhmvPUETzGeFXeKZeKcEEyumTyk77NUfNQIogSK7JSkuSSlN1maRnyk-VGLkX-_UUVqTNOhTqG66Q7jno64jT9Pf40TGvkrRNo5jIXbSCGRTn1nYwJCw2aO-rPkKoetzrC91B-zU6hvQnK2ealc9ivGxma_gU0i-VKXKLSLdhVRa8fCTqI4A |
link.rule.ids | 230,309,783,888,25576,76876 |
linkProvider | European Patent Office |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdR3LTsMwzBoDMW4wQOO5HFBvFfTdHSpE200b7KVpoN2mpE3FDjTT0gF_xIfwY7jVClx2i5LIcqz4GdsBuOGWETG0M9RWZJuqGaPDypjWUnUr0Tg1bDumeYHzYGh3n83HmTWrwGtZC1P0Cf0omiMiR0XI71khr5d_QaywyK2Ut2yBU-K-M_VCpfSOTU3XXSX0vfZ4FI4CJQg8f6IMJ15hGjvuww7sooHt5LzQfvHzmpTlf4XSOYS9McJKsyOoLLM61ILy37U67A82z9043HCePIZeiFflncZCkpiTiK6Y-KRvC9Q8lHAi-ZqspSCpIHm3WZqH_ES-MRY8_f6ikpQZp1yeQLPTngZdFXGa_x5_7k9K5I1TqKYi5Q0gmkFj6loR4wYaNHfUTZCqTmy0uOug_ErOoLENyvn2pSbUutNBf97vDZ8u4KBsaqi7l1DNVmt-hQo4Y9cF7X4AoC6L0w |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=Derivados+de+carboxamidina+e+seu+uso+no+tratamento+de+doen%C3%A7as+vasculares&rft.inventor=LASZLO+DENES&rft.inventor=ZITA+JEGESNE+CSAKAI&rft.inventor=MAGDOLNA+BATHONE+TOROK&rft.inventor=LASZLO+UROGDI&rft.inventor=EDE+MARVANYOS&rft.date=2004-12-28&rft.externalDBID=A&rft.externalDocID=BR0306778A |